Saffron Crocus sativus L.
Also called: saffron crocus
Saffron is the spice made from the dried stigmas of the saffron crocus, a plant known only in cultivation. It has been used in traditional medicine for centuries; supplements contain saffron stigma or its extracts.
- Category
- Botanical
- Part used
- Stigma (dried)
- Strongest evidence
- B Some positive trials
- Native range
- A cultigen known only in cultivation; POWO records it as "a cultigen from Greece"
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2026 meta-analysis (Nutr Neurosci) included 34 RCTs (1,769 adults) of saffron for depression, anxiety and mood, limited to trials of at least 4 weeks in which saffron was the sole difference between groups. [2]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBrain, mood and sleep3 topics
BHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Depressive symptoms | B | A meta-analysis of 23 randomized trials found large effects versus placebo (g = 0.99) and as an add-on to antidepressants; it also found evidence of publication bias and little regional diversity. [1] |
| Anxiety symptoms in adults | B | A 34-trial meta-analysis (1,769 adults) found lower self-rated anxiety (BAI, 6 trials) than placebo but no significant effect on clinician-rated anxiety (HARS); heterogeneity was high. [2] |
| Premenstrual syndrome and period pain | B | A meta-analysis of randomized trials reported reduced PMS symptoms (SMD −0.64, 95% CI −0.84 to −0.44) and reduced dysmenorrhea (SMD −0.51, 95% CI −1.01 to −0.01). [3] |
| Mild cognitive impairment and Alzheimer's disease | C | A meta-analysis of four randomized trials found better cognitive scores than placebo, but the authors judged the evidence insufficient for any recommendation for clinical use. [4] |
Main constituents: Crocin, crocetin and safranal, with phenolic compounds [5]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 30 mg/day for 10 weeks in a double-blind trial in 50 men with obsessive-compulsive disorder, described as well tolerated. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingA 2025 review states that saffron use during pregnancy raises safety concerns …
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Doses above 5 g/day may lead to adverse effects in humans. [5]
- Use during pregnancy raises safety concerns; the one cited pregnancy trial used a low dose for a short time and excluded high-risk pregnancies. [5]
- A meta-analysis of 12 depression trials found no difference in adverse-effect rates between saffron and placebo or antidepressants. [6]
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [8]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Crocins (glycosyl esters of crocetin, e.g. crocin-1, a digentiobioside of crocetin) and crocetin Apocarotenoids (carotenoid-derived pigments) [P1]
- Picrocrocin (glycoside of safranal; main bitter constituent, about 3.7% of stigma weight) Monoterpene glycoside [P1]
- Safranal (aglycone of picrocrocin; about 60% of total volatile content; not present in fresh stigmas, its level depends on drying and storage conditions) Monoterpene aldehyde [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming saffron (Crocus sativus) (NDI 929 submitted 2016-05-21). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- A 2023 review (J Nat Prod, "Botanical Ingredient Forensics", by authors from the ABC-AHP-NCNPR Botanical Adulterants Prevention Program) lists the sale of red-colored corn stigmas, pomegranate fruit peel or fibers, red-dyed silk fibers, safflower stigmas and calendula flowers as saffron stigmas, and the addition of azo dyes to saffron. The program's saffron bulletin is Girme A, et al., Adulteration of saffron and saffron extracts (2022). [P4]
- A survey of saffron samples reported that only 40% belonged to ISO Category I; the average adulteration in the remaining samples was 36.25%. [P5]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of the dietary ingredient (at least one appropriate test or examination) — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petitioned under 111.75(a)(1)(ii). [P6]
- Microscopic examination of stigmas for look-alike plant material — Husaini et al. 2022 report fake look-alike saffron; smartphone microscopy (Foldscope) with toluidine blue staining distinguished genuine from fake saffron. [P5]
- Screening for undeclared synthetic (azo) dyes — Addition of azo dyes to saffron is reported. [P4]
Supply and conservation
- Saffron is the dried stigmas of the flower; flowers are usually picked by hand in the early morning around mid-October, and about 70,000–200,000 flowers are required per kg. More than 90% of world saffron comes from Iran. [P1]
Absorption in people
- Pharmacokinetic studies show that crocin is not available in the blood circulation after oral administration; crocin is converted to crocetin in the intestine, and a large portion of crocin is eliminated via feces. [P7]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- A 2025 review states that saffron use during pregnancy raises safety concerns; in the trial it cites in full-term pregnant women (saffron tablets, 750 mg within 24 h), the dose and duration were low and high-risk pregnancies were excluded. [P1]
Sources for this profile
- Ziani A, et al. Phytochemistry, Biological Activities, Molecular Mechanisms, and Toxicity of Saffron (Crocus sativus L.): A Comprehensive Overview. Antioxidants (Basel) 2025;14(12):1433 (MDPI; PMID 41462633), 2025-11-28. europepmc.org
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (agents classified by the IARC Monographs; checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- Gafner S, Blumenthal M, Foster S, Cardellina JH 2nd, Khan IA, Upton R. Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements. J Nat Prod 2023;86(2):460-472 (American Chemical Society), 2023-02-24. pmc.ncbi.nlm.nih.gov
- Husaini AM, et al. The menace of saffron adulteration: Low-cost rapid identification of fake look-alike saffron using Foldscope and machine learning technology. Front Plant Sci. 2022;13:945291, 2022-08-12. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- Hosseini A, Razavi BM, Hosseinzadeh H. Pharmacokinetic Properties of Saffron and its Active Components. Eur J Drug Metab Pharmacokinet. 2018;43(4):383-390, 2018-08. pubmed.ncbi.nlm.nih.gov
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
Sources
- Marx W, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutr Rev 2019;77(8):557-571 (PMID 31135916), 2019-08-01. pubmed.ncbi.nlm.nih.gov
- Mahmoudi R, et al. Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials. Nutr Neurosci 2026;29(7):816-837 (PMID 41693488), 2026-07. pubmed.ncbi.nlm.nih.gov
- Mohammadi MM, Karimi Z. Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. Korean J Fam Med 2026;47(1):69-80 (PMID 41151539), 2025-10-28. pubmed.ncbi.nlm.nih.gov
- Ayati Z, et al. Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials. BMC Complement Med Ther 2020;20:333 (PMID 33167948), 2020-11-09. pubmed.ncbi.nlm.nih.gov
- Phytochemistry, biological activities, molecular mechanisms, and toxicity of saffron (Crocus sativus L.): a comprehensive overview. Antioxidants (Basel) 2025;14(12):1433 (PMID 41462633; full text via Europe PMC), 2025-11-28. europepmc.org
- Safety and efficacy of saffron (Crocus sativus L.) for treating mild to moderate depression: a systematic review and meta-analysis. J Nerv Ment Dis 2020 (PMID 32221179), 2020-04. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Crocus sativus L. (accessed 2026-10-28; Kew cannot warrant the accuracy of the data). powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.